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L-dopa is the most eﬀective, currently available treatment for Parkinson’s disease (PD), but it leads to the development of invol-
untary movements known as L-dopa-induced dyskinesia (LID) in the majority of patients after long-term use. Both gene and
cell therapy approaches are the subject of multiple ongoing studies as potential ways of relieving symptoms of PD without the
complication of dyskinesia. However, the spectre of dyskinesia in the absence of L-dopa, the so-called “oﬀ-phase” or graft-induced
dyskinesia(GID),remainsamajorobstacleparticularlyinthefurtherdevelopmentofcelltherapyinPD,butitisalsoaconcernfor
proponentsofgenetherapyapproaches.LIDresultsfromnonphysiologicaldopaminerelease,supersensitivityofdopaminerecept-
ors, and consequent abnormal signalling through mechanisms of synaptic plasticity. Restoration of physiological circuitry within
the basal ganglia loops is ultimately the aim of all cell and gene therapy approaches but each using distinctive strategies and accom-
paniedbyrisksofexacerbationofLIDordevelopmentof“oﬀ-phase”/GID.Inthispaperwediscussthedetailsofwhatisunderstood
regarding the development of dyskinesias with relevance to cell and gene therapy and potential strategies to minimize their occur-
rence.
1.Introduction
L-dopa is the most eﬀective treatment for Parkinson’s dis-
ease currently available and for many patients can provide
eﬀective relief of symptoms for many years after diagnosis.
In most patients, L-dopa treatment leads to a “honeymoon”
period during which the motor symptoms are well con-
trolled. However, after 5 years of treatment, approximately
40%ofpatientswilldevelopﬂuctuationsinsymptomcontrol
in response to the drug, as well as involuntary movements
known as “L-dopa-induced dyskinesias” (LID) [1]. These
complications aﬀect as many as 89% of PD patients after 10
years of L-dopa treatment [2]. LID can be seen during “peak
dose”periods,during“oﬀ”medicationperiodsorina“biph-
asic” pattern as L-dopa levels rise and fall following oral
intake. For this reason, other strategies have been developed
to try and restore normal function of the basal ganglia cir-
cuitry. Deep brain stimulation (DBS) of the subthalamic
nucleus (STN) or globus pallidus pars interna (GPi) have
both been shown to be highly successful ways of controlling
symptoms of PD. Dyskinesia is generally reduced following
STN DBS as a result of reduction in L-dopa dose. GPi DBS
is a highly eﬀective way of reducing LID, but many patients
remain reliant on frequent high doses of L-dopa to maintain
c o n t r o lo fP Ds y m p t o m s[ 3, 4].
To improve upon the limitations of currently available
therapies, studies are being performed to assess the role of
either gene therapy or cell therapy to provide PD symptom
relief without the complication of dyskinesia. Cell therapy
trials have been seriously hindered by reports of dyskinesia
occurring in the absence of L-dopa—the so-called “oﬀ-
phase” or graft-induced dyskinesia (GID) [5, 6]. There are
also theoretical concerns that such “oﬀ-phase” dyskinesias
might limit the ability of gene therapy to lead to an eﬀective
PDtherapy.Asapreludetodiscussingtheoriginof“therapy-
” induced dyskinesia, and strategies to minimize or control
them, a discussion of our current understanding of LID is
required.2 Parkinson’s Disease
2. Origin of LID
Risk factors for the development of LID include younger age
[7, 8], dose of L-dopa [9], pattern of L-dopa administration
[9–12], and stage of disease [13–15]. The neural mechanisms
that underlie LID in PD are not completely understood;
however, the study of basal ganglia anatomy and physiology
in the normal and dopamine-depleted states has been of
great help. In PD, the degeneration of the dopaminergic
neurons of the substantia nigra compacta (SNc) compro-
mises the equilibrium between the direct (D1 receptor)
and indirect (D2 receptor) pathways resulting in abnormal
GPi hyperactivity. Initially, the clinical features of PD were
thought to follow simple increases in the “rate” of activity
of the GPi, which through inhibition of the motor thalamus
acted as a brake to activity in the supplementary motor area.
It was further considered that excessive levodopa stimulation
might induce dyskinesia by reduction of the inhibition of
thalamocorticalneuronsresultinginanoveractivityofmotor
cortical areas [16].
This model, is however, inconsistent with several clinical
and experimental ﬁndings. During LID in the nonhuman
primate model of PD, there is decreased rather than
increased metabolic activity in the ventral anterior (VA) and
ventrolateral (VL) thalamic nuclei, regions of the thalamus
that receive input from the GPi [17]. Furthermore, among
patients with PD and LID, creation of a lesion within the GPi
(pallidotomy) is associated with a reduction in LID rather
than a deterioration in LID that would have been predicted
by the previously described “rate model” [18].
The pathophysiological changes that underlie the devel-
opment of LID must therefore be far more complex. Record-
ings taken from PD patients undergoing DBS surgery have
revealed that during periods of LID there is an increase in 4–
10Hz activity in the contralateral STN, suggesting that there
is an abnormal pattern of oscillatory activity throughout the
basal ganglia [19]. The cause of this oscillatory activity is
likely to be multifactorial involving both pre and post synap-
tic components.
2.1. Dysfunctional Dopamine Release. The surviving dopam-
inergic neurons in the progressively denervated striatum,
sprout branches that successfully compensate for the neu-
rodegenerative process until ∼60% of neurons, are lost.
Until this point, administration of L-dopa does not alter
the concentration of striatal dopamine, but beyond the
60% deﬁcit, the concentration of dopamine in the striatum
increases 3-fold after L-dopa administration [20]. While L-
dopa administration continues to enhance dopamine syn-
thesis and release by the surviving dopaminergic neurons,
L-dopa is also decarboxylated and released as dopamine
by serotonergic terminals, noradrenergic neurons, striatal
capillaries, and nonaminergic striatal interneurons [20–23].
These terminals do not store and release dopamine in a regu-
lated way, thus leading to nonphysiological dopamine recep-
tor stimulation [24].
The role of serotonergic neurons in the development of
LID has been the subject of particular study. In rats with 6-
hydroxy dopamine lesions, approximately 80% of the peak
dopamine (DA) eﬄux measured in the striatum following
the administration of L-dopa originates from serotonergic
neurons [25–28].This nonphysiological DA release is highly
dyskinesigenic; indeed recent evidence shows that dyskinetic
rodents have increased numbers of serotonergic terminals
and sprouting of serotonin axon varicosities stimulated by
L-dopa exposure, leading to larger swings of extracellular DA
release [29].
2.2. Dopamine Receptor Supersensitivity. Under conditions
of chronic denervation, dopamine receptors develop super-
sensitivity, involving an increased expression of receptors
on the postsynaptic membrane of medium spiny neurons
[30,31].D1receptorsupersensitivityhasbeenshowntohave
a direct relationship with LID severity [32]. Persistent stimu-
lation of dopamine receptors normally leads to their desen-
sitisation and induces receptor internalisation, and it is
hypothesised that, in LID, this desensitisation and internali-
satio np r oc essisimpair ed[33–35].Inarodent modelofLID,
it seems that D1 receptors become “anchored” on the plasma
membrane of medium spiny neurons due to crosstalk with
D3 receptors following chronic administration of L-dopa
[34]. Consistent with this it has been shown that the use of a
D3 antagonist restores normal levels of D1 receptors on the
plasma membrane and has been associated with reduction in
LID in both the rodent and primate models [36, 37]. How-
ever, it is clear that LID does not occur solely as a result of
abnormal D1 receptor expression or sensitivity alone since
D2 selective agonists can also provoke dyskinesia [38].
2.3. Synaptic Plasticity. Physiological dopaminergic input
from nigrostriatal neurons onto the striatal medium spiny
neurons plays an important role in the potentiation and
depotentiation of synapses of the corticostriatal pathway.
Repetitivestimulationcancauseeitheralong-lastingincrease
in synaptic strength known as long-term potentiation (LTP),
or an enduring decrease known as long-term depression
(LTD), a phenomenon known as synaptic plasticity [39,
40]. It is this process that allows deletion of unwanted
or unnecessary connections and strengthening of desirable
motor programs.
Disruption of normal synaptic plasticity is strongly link-
edtotheappearanceofdyskinesia[41–45].Itishypothesized
that the disrupted motor control underlying dyskinesia is
attributable to speciﬁc changes occurring along the dopam-
ine D1 receptor/protein kinase A/dopamine and cyclic AMP-
regulated phosphoprotein-32 (D1/PKA/DARPP-32) intra-
cellular signalling pathway leading to the loss of synaptic
depotentiation at corticostriatal synapses and to the devel-
opment of nonphysiological motor circuits within the basal
ganglia [39].
L-dopa can restore normal synaptic plasticity among
individuals free of dyskinesia, but not when dyskinesias are
already developed [46]. It has been proposed that patients
with LID have lost the ability to depotentiate synapses nor-
mally, that is, they have lost the mechanism that underlies
“synaptic forgetting,” resulting in pathological storage of
information that would normally be erased, leading to
the development of abnormal motor patterns, that is,Parkinson’s Disease 3
LID [42, 47]. Possible consequences of this process in-
clude increased phosphorylation of N-methyl-D-aspartate
(NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) receptor subunits [48] and increased
striataldynorphinmRNAlevels[49].Ameliorationofabnor-
mal glutamatergic NMDA transmission likely explains the
beneﬁcial eﬀects of Amantadine [50–52] on reversal of LID.
3.Graft-InducedDyskinesia
Graft-induced dyskinesia (GID) was ﬁrst brought to wide-
spreadattentionfollowingthepublicationoftherandomised
sham-surgery-controlled trials of fetal dopaminergic cell
transplantation[5,6].GIDsarecharacterizedbythepresence
of both hyperkinesias and dystonic postures occurring in the
“oﬀ phase,” generally considered to be greater than 12 hours
following the last dose of L-dopa. In the Freed trial, “oﬀ
phase” GID was seen in 5/33 (15%) of transplanted patients,
more than 1 year after transplant [5]. The second sham-sur-
gery-randomised-controlled trial (Olanow trial) reported
the presence of “oﬀ-phase” GID in 13/23 (56.5%) of the
grafted patients, 6–12 months after transplantation [6]. In 3
ofthepatientsfromtheOlanowtrialtheGIDsweredisabling
enough to require further neurosurgical intervention [6].
In contrast to the worrying appearance of “oﬀ-phase” GID,
neithertrialreportedanyincreaseinL-dopa-inducedor“on-
phase” dyskinesia.
Patients receiving open label transplants that predated
the Freed and Olanow trials had also experienced GID [53–
55] but these had caused only mild to moderate disability to
the patients even with follow-up extending to 11 years [55].
Speculation regarding the origin of “oﬀ-phase” dyskinesias
has included the possibility of excessive dopamine produc-
tion by the grafts, dopamine receptor supersensitivity away
from “islands” of grafted cells, individual factors related to
the patient and their PD phenotype, a relationship with
immune rejection, or contamination of the grafts with cells
of a nondopaminergic phenotype.
3.1. Excess Dopamine Release? Initial hypotheses were that
GID occurred due to excessive dopamine release by the
grafts. This has not, however, been supported by functional
imaging of the patients in the Olanow trial or the Hagell
patient series [55–57]. Dyskinesia severity was not related to
the magnitude of graft-derived dopaminergic reinnervation,
asjudgedby18F-dopapositronemissiontomography(PET),
indicatingthat“oﬀ-phase”dyskinesiasprobablydonotresult
from excessive growth of grafted dopaminergic neurons.
Furthermore, the severity of GID was not correlated with
improvement in the “oﬀ”U P D R Sm o t o rs c o r e s[ 55, 58]. The
fact that GIDs have not been seen in patients without any
beneﬁt from their transplants suggests that a functional graft
is necessary for GID development although their appearance
does not simply relate to excess dopamine release.
3.2. Imbalanced Dopamine Release? It was further proposed
that islands of excessive dopaminergic activity might relate
to GID [59]. Indeed the patients with the best functional
outcome after transplantation exhibited no dopaminergic
denervation in areas outside the grafted areas, either preop-
eratively or at 1 or 2 years postoperatively. Comparing PET
signal among patients with and without GID, there was a
greater increase of putaminal 18F-Dopa uptake seen in the
posterodorsal zone of GID patients. However, the GID group
also showed a relative increase ventrally not seen at all in the
GID-negative patients suggesting that unbalanced increases
in dopaminergic function might complicate the outcome of
neuronal transplantation for parkinsonism. The implanta-
tion of dopamine cells into the ventrocaudal putamen, may
also contribute to the unusual distribution of GID, in which
the face, neck, and arms tend to be the most clinically involv-
ed. These data are corroborated by animal models showing
that dyskinesias occur following transplantation of cells to a
particular prodyskinetic subregion of the putamen [49].
3.3. Patient Phenotype? In the same clinical studies, the
severityofGIDwasnotfoundtocorrelatewiththeseverityof
pretransplant L-dopa-induced dyskinesias (LID). However, a
negative correlation was seen between the severity of post-
operative “oﬀ-phase” GID and preoperative putaminal 18F-
Dopa uptake [55, 57]. This ﬁnding indicates that the mani-
festation of “oﬀ-phase” dyskinesias after grafting, similar
to that of L-dopa-induced “on-phase” dyskinesias [60, 61]
might be related to the baseline severity of striatal dopamin-
ergic denervation.
3.4. Tissue Storage? In the Freed trial, cells were stored for
up to 4 weeks before transplantation, In the Hagell series, the
appearanceofGIDwasreportedinpatientswithgraftsstored
for1–8days.However,anyhypotheticalrelationshipbetween
tissue storage and GID hypothesis was not supported by the
Olanow trial, in which no grafts were stored for >48 hours.
3.5. Immunosuppression? In the Olanow trial, the initial
signiﬁcant improvement in the grafted patients compared
with sham-operated cases [6] was lost following withdrawal
of immune suppression after 6 months. Also in two patients
who came to autopsy, the grafts were surrounded by activat-
ed microglia suggesting an immune response [6]. Such
inﬂammatory reactions could lead to reduced graft survival
and functional deterioration [62, 63]. GIDs develop slowly
over time and appear to be most pronounced in patients
that have received no immune-suppression [5] or only mild
immunosuppressive treatment [56]. There has been specula-
tion, therefore, that such an ongoing inﬂammatory/immune
process could aﬀect the way the grafted DA neurons release
and/or handle DA at the synaptic level, which in turn may
constitute a triggering factor for the induction of dyskinesias
[64].
3.6. Serotonergic Contamination? It has now been shown
that in 2 patients experiencing GID, there was excessive
serotonergic innervation in their brains following trans-
plant, (252–285% higher than comparable advanced PD
patients). This was measured using functional imaging
with ((11)C)-3-amino-4-(2-dimethylaminomethyl-phenyl-
sulfanyl) benzonitrile positron emission tomography
(C11-DASB PET). Importantly this excessive serotonergic4 Parkinson’s Disease
innervation was seen restricted to the areas of their grafts.
There is mounting evidence that serotonergic neurons con-
taminating the original graft release dopamine in an uncon-
trolled manner and then lack the ability to reuptake DA and
buﬀer extracellular DA levels leading to GID [65].
4 .T h eR el atio n s h ipbet w ee nL I Dan dGI D
The clinical similarity between LID and GID suggests that
similar pathophysiological mechanisms may underlie the
development of both. Animal models strongly support the
suggestion that the severity of LID in animals that have
received putaminal grafts are related to the number of sero-
tonergic neurons contained within the graft, as well as the
severity of the dopaminergic lesion. Among animals receiv-
ing serotonin grafts [66], there was no impact on either
motor asymmetry in the amphetamine-induced rotation test
or spontaneous forelimb use in the cylinder test, but in con-
trast there was a progressive worsening of LID. Other studies
have also conﬁrmed that removal of serotonin innervation,
or dampening of serotonin neuron activity by agonist drugs,
results in a near complete blockade of LID in 6-OHDA
lesioned rats [27].
It would appear that the relative abundance of dopamin-
ergic compared to serotonergic neurons (whether host or
grafted)isacriticalfactorinLIDdevelopmentaftergraft[67,
68]. It appears that, in the presence of a severe dopaminergic
deﬁcit, dopamine released from serotonergic neurons may
trigger severe dyskinetic responses, but provided ∼10–20%
of the dopamine innervation remained intact, the grafted
serotonin neurons have limited detrimental eﬀect on dysk-
inesia severity. This has been corroborated independently
showing that serotonergic neurons are not detrimental,
provided suﬃcient dopamine neurons remain in the graft
[69].
TheappearanceofLIDaftergraftmayoccurvia(i)dysre-
gulated DA release from serotonergic neurons themselves,
(ii) lack of reuptake of released DA due to insuﬃcient DA
neurons, (iii) inhibition of the dopamine transporter (DAT)
on DA neurons by 5HT release thus preventing DA reuptake
byDAneurons,and(iv)abnormaldopaminereceptorsuper-
sensitivity (i.e., a postsynaptic component) as evidenced by
increases in apomorphine-induced rotations [28, 68].
Despite these consistent ﬁndings of LID appearance fol-
lowing serotonergic contamination of cell grafts, “oﬀ-phase”
dyskinesias (GID) do not appear to occur in animal mod-
els of PD undergoing cell grafts with the exception of very
mild abnormal movements occurring in 2 studies [70, 71].
This is of major importance since there is little or no
relationship between the change in LID following transplan-
tation in patients (which tends to improve) and the devel-
opment of GID. Given that the patients exhibiting GID are
those that had the most severe dopaminergic deﬁcits, in
the absence of exogenous L-dopa administration, it seems
likely that GID appearance must relate to dopamine pro-
duction from the graft itself. Dopamine released into the
extracellular space can be taken up by serotonergic neurons
via the serotonin transporter and subsequently be rereleased
as a false transmitter [72]. Furthermore, serotonin release
can block the dopamine transporter and add to abnormal
accumulation of dopamine in the synaptic cleft and onset
of dyskinesia [65, 73]. Whether serotonergic neurons have a
role in the development of “oﬀ-phase” GID simply by main-
taining postsynaptic dopamine receptors in a supersensitive
state has not yet been conﬁrmed. Any relevance of abnormal
synaptic plasticity as a secondary or parallel process in the
development of GID has also yet to be comprehensively
studied.
5. Gene Therapy for PD and
Its Effects on Dyskinesia
Gene therapy represents an exciting new prospect for the
treatment of patients with PD. This technology exploits the
properties of viral vectors to invade host cells and incor-
porateDNAintothehostgenome.Appropriatemodiﬁcation
of viral vectors allows control over which genes are incor-
porated and within PD research the main focus has been
predominantlyongenesencodinggrowthfactorsorenzymes
involved in dopamine synthesis [74, 75]. Gene transfer oﬀers
a practical means of solving the problems associated with
implanted hardware while still providing a continuous and
selective delivery system of the desired gene/protein at the
targeted site.
There are 4 gene therapy programs that have already
reached the stage of clinical trial evaluation.
5.1.AAV2-Neurturin. AAV2-Neurturin,ananalogueofglial-
cell-derived neurotrophic factor (GDNF), has been devel-
oped in an attempt to provide trophic support to neu-
rons/glia and thus manipulate the progression of PD. Both
(GDNF) and Neurturin enhance dopaminergic neuron sur-
vivalandnigrostriatalfunctioninanimalmodelsofPD.Both
factors provide protection from 6-OHDA-induced degen-
e r a t i o ni nr a t s[ 76] and provide neuroprotection in parkin-
sonian monkeys [77]. In a clinical trial of 58 patients at
12 months, delivery of neurturin to the striatum failed to
showanychangeintheprimaryoutcomemeasure(oﬀ-medi-
cation part III-UPDRS) [78]. There was not any change in
dyskinesia scores in neither the Neurturin nor the sham sur-
gery groups. Retrograde transport to the substantia nigra
pars compacta (SNc) was lower (or possibly slower) than
expected and therefore a follow-up evaluation is underway
targeting both the striatum and SNc. It seems unlikely that
this approach would lead to worsening of dyskinesia severity,
indeed beneﬁcial eﬀects on dopaminergic number, survival
or function should lead in theory to improvement in LID.
Nevertheless, any disproportionate neurotrophic action on
serotonergic neurons might in theory lead to provocation
of dyskinesia, and these should be speciﬁcally sought during
clinical evaluation of patients receiving this treatment.
5.2. AAV2-GAD. Gene therapy consisting of insertion of the
glutamic acid decarboxylase gene (GAD) into the neurons of
theSTNoﬀersanalternativetherapeuticstrategy.Inspiredby
the eﬀectiveness of STN DBS, the hypothesis emerged that
expression of GAD (the rate-limiting enzyme for GABA pro-
duction) would inhibit overactivity in the STN and wouldParkinson’s Disease 5
improve oﬀ-medication UPDRS motor score. This strategy
has been eﬀective in the rat model of PD [79]. It is known
that STN DBS can itself provoke “oﬀ-medication dyskin-
esia” but this is usually a transient phenomenon when it
occurs and may be relieved by adjustment of the stimulation
amplitude. Since the mechanism of action of STN DBS
remains controversial, it remains theoretically possible that
GAD gene therapy might also provoke “oﬀ-phase” dyskine-
sia. However in the results published to date in a double
blind evaluation, no increase in dyskinesias was reported,
while a modest improvement in PD severity was observed
[80]. Open label follow up of these patients will allow fur-
ther quantitative estimates of the extent to which LID may
improve or deteriorate following this approach.
5.3. AAV-hAADC. Bilateral intraputaminal infusion of AAV-
hAADC (adeno-associated virus-human aromatic L-amino
acid decarboxylase), the enzyme that converts L-dopa into
dopamine, aims to improve the conversion of exogenously
administered L-dopa. Since this therapy remains dependent
on exogenous administration of L-dopa, “oﬀ-phase” dyski-
nesia is unlikely to occur. However, striatal transfection with
AAV-hAADC has been shown to increase LID in primate
parkinsonian models if delivered in a nonhomogeneous way
[81], reminiscent of the experience of “oﬀ-phase” graft-
induceddyskinesiaincelltherapyexperiments.Despitethese
theoretical concerns, data published to date have shown an
increase in on-time and reduction in oﬀ-time without any
increase in LID [75]. Two patients had a transient increase in
mild LID, but none experienced “troublesome LID,” which
were reduced for the group as a whole [75].
5.4.LV-TH-GCH1-AADC-ProSavin. TheProSavinapproach
incorporates all 3 enzymes required for dopamine biosyn-
thesis (tyrosine hydroxylase (TH), AADC, and GTP cyclo-
hydrolase L1(GCH1)), with the aim of transfection of
nondopaminergic cells so that they may produce and release
dopamine endogenously. Again the theoretical concern is
that transfected neurons may synthesize dopamine but may
not be able to store and release this dopamine in a phy-
siological manner, and an increase in dyskinesia may follow.
The pilot phases of this program are using a dose escalation
strategy, with careful evaluation of eﬃcacy and dyskinesia
severity at each stage, before proceeding with dose increases
in subsequent patient cohorts. So far, there have been no
concerns regarding “oﬀ-phase” dyskinesias. Further addition
of the vesicular monoamine transporter 2 (VMAT2) gene to
allow dopamine transport by transfected cells has not shown
any advantage over the ProSavin approach in laboratory
experiments [82].
An additional gene therapy program that has not yet
reachedclinicaltrialstageaimstodelivercontinuousdopam-
ine therapy using AAV-TH-GCH1. By omitting the AADC
enzyme, transfected cells would be able to synthesize L-dopa
but rely on endogenous AADC activity to produce dopam-
ine. This reduces the risk of uncontrolled dopamine pro-
duction that cannot be stored or transported physiologically
and aims to deliver “continuous dopaminergic stimulation
(CDS),” to mimic the advantages observed using other
methods of CDS [12]. In rodent models, this therapy has
been shown to allow resistance to LID development [83].
All of the current gene therapy approaches, if successful,
could permit a reduction of L-dopa dose and, therefore,
achieve greater control of LID. No major concerns regarding
“oﬀ-phase” dyskinesias have been reported among patients
exposed to PD gene therapy. However, dose escalation to try
andachievegreatereﬃcacyfromtheseapproacheswillneces-
sitate continued vigilance with regard to dyskinesia emer-
gence.
6. Preventing“Therapy-”InducedDyskinesias
Our knowledge regarding the underlying causes of LID is
growing, and it is clear that the pathophysiological processes
are complex, depending on the number of intact dopamin-
ergic terminals, the chronicity, and pattern of administra-
tion of L-dopa replacement as well as the possibility of
genetic variability in pathways controlling receptor super-
sensitivity/internalization and synaptic plasticity. There is
converging evidence to implicate nondopaminergic neurons,
in particular serotonergic neurons releasing dopamine in a
nonphysiological manner, as a major contributory factor in
LID and also GID.
This knowledge is vital in trying to minimize the like-
lihood of “oﬀ-phase” GID developing in PD patients partic-
ipating in future trials of fetal cell therapy. Careful attention
must be paid to selecting the optimal patients phenotype
with respect to the severity of their PD and by implication
the number of surviving dopaminergic terminals at the time
of transplantation. Patients with advanced dopaminergic
degeneration will be at greater risk of developing dyskinesia
from grafts that contain an excessive number of serotonergic
neurons. Patients with less advanced dopaminergic cells
loss should be more tolerant of a greater number of sero-
tonin contaminating cells. The relative extent of dopamine/
serotoninstriatalinnervationscanberevealedusingpreoper-
ative functional imaging, to quantify the extent and severity
of both dopaminergic and serotonergic innervations in the
striatum.
The perioperative and intraoperative details are also
extremely important. It is possible to manipulate the num-
ber of contaminating serotonergic neurons within grafts,
throughoptimisationofthedissectionmarginsintheventral
mesencephalon of the fetal tissue, during graft harvesting.
Furthermore, clinical and animal data both suggest that
surgical targeting should avoid the ventral putamen. While
thetypeanddurationofimmunosuppressiveregimesmayor
maynothavemajorrelevanceforGIDdevelopment,itislike-
ly that overall cell survival is improved by maintaining
immunosuppression for longer than the 6 months adopted
in previous cell therapy trials.
6.1. Additional Use of Nondopaminergic Medications. The
use of serotonin (5HT-1A) agonists as antidyskinetic agents
is not new. Buspirone, a (5-hydroxytryptamine (5HT 1A)
receptor agonist, has previously showed beneﬁcial eﬀects
lessening the severity of LID [84], by dampening transmitter
release from serotonergic neurons through activation of6 Parkinson’s Disease
inhibitory 5HT-1A autoreceptors without any worsening
of extrapyramidal symptoms. Beneﬁcial eﬀects seen among
patients with GID have also been reported [65]. Sarizotan
(also a 5-HT1A receptor agonist but with additional high
aﬃnityforD3andD4receptors)showedencouragingresults
in an open-label evaluation [85]; however, in a blinded trial
the eﬀects of Sarizotan on LID were disappointing [86].
While the mechanism(s) remain unclear, one likely explana-
tion for the possible beneﬁcial eﬀect of serotonin receptor
agonists on LID is that stimulating 5HT1A receptors dimin-
ish dysregulated release of dopamine from raphe-striatal
serotonergic neurons. However, it has also been shown
that 5HT1A agonist drugs alleviate dyskinesias provoked by
direct D1 receptor agonists, suggesting a further interaction
between D1 and 5-HT1A receptors [87].
The beneﬁcial eﬀects of Amantadine on LID through its
action on NMDA receptors have prompted further study
of agents acting on the corticostriatal glutamatergic input
evaluating the eﬀects of metabotropic glutamate receptor
(mGLUR) antagonists and Adenosine A2A receptor antag-
onists. AFQ056 is a potent, selective mGLUR5 antagonist
that shows antidyskinetic eﬀects in a rodent PD model and
has been shown to have signiﬁcant antidyskinetic eﬀects in 2
small blinded trials [88]. Istradefylline (an A2A antagonist)
has been shown to improve motor function and reduce the
development of LID in nonhuman primates [89]; indeed
rodent A2a knockout animals do not develop LID [90].
In patients with PD, however, multiple randomised trials
have failed to show beneﬁcial eﬀects of Istradefylline on LID
severity[80,91].α2Adrenergicagonistsmodulatetheactivity
of the direct striatopallidal pathway and have been shown to
reduce LID in PD patients but their use in PD patients has
been limited by development of side eﬀects [92, 93]. Given
the demonstration of beneﬁcial eﬀects in animal models
[36, 37], a further emerging possibility might be the use of
D3 antagonists to allow D1 receptor internalisation, with the
aim of reducing the postsynaptic “supersensitive” state [94];
however, this approach has yet to be evaluated in patients.
7. Conclusions
The current and future gene therapy and cell therapy pro-
grams represent a great source of optimism for patients
with PD. However, PD is a heterogeneous disease and only
a subset of patients are likely to beneﬁt—perhaps the sub-
group of patients with young onset PD that remain with a
predominantly motor deﬁcit for many years [95]. In these
individuals, LID is a major problem and the success of cell
or gene therapy will depend on providing relief of PD “oﬀ”
symptoms without “oﬀ-phase”/therapy-induced dyskinesia.
Dyskinesia development has multiple determinants, and
therefore multiple potential opportunities exist to intervene
andpreventtheiroccurrence.Someoftheseprocessesmaybe
relevant solely as a secondary consequence of nonphysiolog-
ical dopamine release (presynaptic component) from seroto-
nergic or other neurons, or as a downstream eﬀect of chro-
nic dopamine receptor supersensitivity (postsynaptic com-
ponent). Consequent downstream changes in synaptic plas-
ticity may account for abnormal oscillatory ﬁring patterns,
throughout the basal ganglia circuitry. L-dopa itself (pre-
sumablywhenreleasedphysiologically)hasbeenidentiﬁedas
having a role in the restoration of normal synaptic plasticity,
as evidenced from recordings of patients undergoing high-
frequency stimulation of the substantia nigra pars reticulata,
in both on- and oﬀ-medication states [96, 97]. Whether
other pharmacological options such as Buspirone, AFQ056,
or D3 receptor antagonists can be exploited to relieve oﬀ-
medication GID needs further study.
In parallel with approaches to relieve LID and GID, our
understanding of the importance of the ratio of serotonin
and dopaminergic neurons allows optimisation of future
interventions and accompanying trial design. Our greater
understanding of the causes of dyskinesia, either L-dopa
related or graft and gene therapy induced, represents a con-
siderablesteptowardsensuringthesuccessoffuturegeneand
cell therapy programs.
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